CL2017001181A1 - Amidas de morfolina y 1,4-oxazepano como agonistas del receptor de somatostatina subtipo 4(sstr4) - Google Patents
Amidas de morfolina y 1,4-oxazepano como agonistas del receptor de somatostatina subtipo 4(sstr4)Info
- Publication number
- CL2017001181A1 CL2017001181A1 CL2017001181A CL2017001181A CL2017001181A1 CL 2017001181 A1 CL2017001181 A1 CL 2017001181A1 CL 2017001181 A CL2017001181 A CL 2017001181A CL 2017001181 A CL2017001181 A CL 2017001181A CL 2017001181 A1 CL2017001181 A1 CL 2017001181A1
- Authority
- CL
- Chile
- Prior art keywords
- sstr4
- oxazepane
- subtype
- morpholine
- amides
- Prior art date
Links
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 title abstract 3
- -1 1,4-oxazepane amides Chemical class 0.000 title 1
- 229940127504 Somatostatin Receptor Agonists Drugs 0.000 title 1
- 238000000034 method Methods 0.000 abstract 2
- ZNGWEEUXTBNKFR-UHFFFAOYSA-N 1,4-oxazepane Chemical compound C1CNCCOC1 ZNGWEEUXTBNKFR-UHFFFAOYSA-N 0.000 abstract 1
- 102000005157 Somatostatin Human genes 0.000 abstract 1
- 108010056088 Somatostatin Proteins 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 abstract 1
- 229960000553 somatostatin Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/10—Seven-membered rings having the hetero atoms in positions 1 and 4 not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14193185 | 2014-11-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2017001181A1 true CL2017001181A1 (es) | 2018-02-02 |
Family
ID=51904765
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2017001181A CL2017001181A1 (es) | 2014-11-14 | 2017-05-10 | Amidas de morfolina y 1,4-oxazepano como agonistas del receptor de somatostatina subtipo 4(sstr4) |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US10071974B2 (2) |
| EP (1) | EP3218372B1 (2) |
| JP (1) | JP6641367B2 (2) |
| KR (1) | KR20170082632A (2) |
| CN (1) | CN107108592B (2) |
| AU (1) | AU2015345070A1 (2) |
| BR (1) | BR112017009595A2 (2) |
| CA (1) | CA2965566A1 (2) |
| CL (1) | CL2017001181A1 (2) |
| EA (1) | EA032104B1 (2) |
| IL (1) | IL251465A0 (2) |
| MX (1) | MX370366B (2) |
| PH (1) | PH12017500821A1 (2) |
| WO (1) | WO2016075240A1 (2) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO2699580T3 (2) | 2014-01-24 | 2018-02-24 | ||
| EP3053452A1 (en) * | 2015-01-16 | 2016-08-10 | Interquim, S.A. | Naturally derived colour stabilizer |
| WO2018022978A1 (en) * | 2016-07-29 | 2018-02-01 | Insmed Incorporated | Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating bronchiectasis |
| US20200087390A1 (en) | 2016-12-21 | 2020-03-19 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| US11912687B2 (en) | 2017-05-12 | 2024-02-27 | Board of Trustees of the Southern Illinois University | 3,4,5-trisubstituted-1,2,4-triazoles and 3,4,5-trisubstituted-3-thio-1,2,4-triazoles and uses thereof |
| EP3634406B1 (en) | 2017-05-12 | 2023-09-06 | Board of Trustees of The Southern Illinois University on behalf of Southern Illinois University Edwardsville | 3,4,5-trisubstituted-1,2,4-triazoles and 3,4,5-trisubstituted-3-thio-1,2,4-triazoles and uses thereof |
| FI3758708T3 (fi) | 2018-03-01 | 2025-02-18 | Astrazeneca Ab | (2s)-{(1s)-1-syano-2-[4-(3-metyyli-2-okso-2,3-dihydro-1,3-bentsoksatsol-5-yyli)fenyyli]etyyli}-1,4-oksatsepaani-2-karboksamidia käsittäviä farmaseuttisia koostumuksia |
| TWI834637B (zh) * | 2018-03-01 | 2024-03-11 | 日商武田藥品工業有限公司 | 六氫吡啶基-3-(芳氧基)丙醯胺及丙酸酯 |
| KR20210032431A (ko) | 2018-07-17 | 2021-03-24 | 인스메드 인코포레이티드 | 루푸스 신염을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카복스아미드 |
| AR121683A1 (es) * | 2020-03-31 | 2022-06-29 | Takeda Pharmaceuticals Co | Derivados de n-heteroarilalquil-2-(heterociclil y heterociclilmetil)acetamida como agonistas de sstr4 |
| CN113717161B (zh) * | 2020-05-21 | 2023-06-09 | 广州费米子科技有限责任公司 | 含氮饱和杂环化合物及其制备方法、药物组合物和应用 |
| WO2022012534A1 (zh) * | 2020-07-13 | 2022-01-20 | 广州费米子科技有限责任公司 | 含氮杂环化合物、药物组合物和应用 |
| AR127055A1 (es) | 2021-09-14 | 2023-12-13 | Lilly Co Eli | Sales agonistas de sstr4 |
| EP4646265A1 (en) | 2023-01-06 | 2025-11-12 | Insmed Incorporated | Novel, reversible dpp1 inhibitors and uses thereof |
| WO2025027049A1 (en) | 2023-08-02 | 2025-02-06 | Boehringer Ingelheim International Gmbh | (2s,5r)-5-(hydroxymethyl)morpholine-2-carboxamides as agonists of sstr4 |
| WO2025247982A1 (en) | 2024-05-29 | 2025-12-04 | Grünenthal GmbH | Piperazines which act as sstr4 modulators |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2377758T3 (es) * | 2004-11-12 | 2012-03-30 | Bristol-Myers Squibb Company | Compuestos tricíclicos basados en tiazolo[4,5-b]piridina imidazo-fusionada y composiciones farmacéuticas que los comprenden |
| WO2010059922A1 (en) * | 2008-11-21 | 2010-05-27 | Ligand Pharmaceuticals Incorporated | Pyrrolidine carboxamide compounds |
| WO2012120476A1 (en) | 2011-03-10 | 2012-09-13 | Lupin Limited | Substituted morpholines as modulators for the calcium sensing receptor |
-
2015
- 2015-11-12 CA CA2965566A patent/CA2965566A1/en not_active Abandoned
- 2015-11-12 EA EA201791058A patent/EA032104B1/ru not_active IP Right Cessation
- 2015-11-12 BR BR112017009595A patent/BR112017009595A2/pt not_active Application Discontinuation
- 2015-11-12 EP EP15793840.8A patent/EP3218372B1/en active Active
- 2015-11-12 AU AU2015345070A patent/AU2015345070A1/en not_active Abandoned
- 2015-11-12 CN CN201580062239.4A patent/CN107108592B/zh active Active
- 2015-11-12 US US15/526,361 patent/US10071974B2/en active Active
- 2015-11-12 WO PCT/EP2015/076440 patent/WO2016075240A1/en not_active Ceased
- 2015-11-12 KR KR1020177016161A patent/KR20170082632A/ko not_active Withdrawn
- 2015-11-12 MX MX2017006231A patent/MX370366B/es active IP Right Grant
- 2015-11-12 JP JP2017525799A patent/JP6641367B2/ja active Active
-
2017
- 2017-03-30 IL IL251465A patent/IL251465A0/en unknown
- 2017-05-04 PH PH12017500821A patent/PH12017500821A1/en unknown
- 2017-05-10 CL CL2017001181A patent/CL2017001181A1/es unknown
-
2018
- 2018-07-30 US US16/048,665 patent/US10577336B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2017533930A (ja) | 2017-11-16 |
| JP6641367B2 (ja) | 2020-02-05 |
| US10577336B2 (en) | 2020-03-03 |
| AU2015345070A1 (en) | 2017-04-20 |
| US20180339971A1 (en) | 2018-11-29 |
| MX2017006231A (es) | 2017-07-31 |
| CN107108592B (zh) | 2021-01-29 |
| KR20170082632A (ko) | 2017-07-14 |
| EP3218372B1 (en) | 2020-05-20 |
| US10071974B2 (en) | 2018-09-11 |
| MX370366B (es) | 2019-12-11 |
| CN107108592A (zh) | 2017-08-29 |
| EA032104B1 (ru) | 2019-04-30 |
| EA201791058A1 (ru) | 2017-11-30 |
| WO2016075240A1 (en) | 2016-05-19 |
| EP3218372A1 (en) | 2017-09-20 |
| BR112017009595A2 (pt) | 2017-12-19 |
| PH12017500821A1 (en) | 2017-10-02 |
| CA2965566A1 (en) | 2016-05-19 |
| IL251465A0 (en) | 2017-05-29 |
| US20170320838A1 (en) | 2017-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12017500821A1 (en) | Morpholine and 1, 4-oxazepane amides as somatostatin receptor subtype 4 (sstr4) agonists | |
| UY35572A (es) | Nuevos agonistas del receptor de somatostatina subtipo 4 (sstr4) | |
| CL2018001230A1 (es) | Tratamiento de osteoartritis | |
| ECSP18060342A (es) | Derivados de tiohidantoína sustituidos como antagonistas del receptor de andrógenos | |
| MX379110B (es) | Derivados de azaspiro como antagonistas de trpm8. | |
| NI201600144A (es) | Derivados de quinoxalina utiles como moduladores del fgfr cinasa | |
| CL2016002148A1 (es) | Derivados de fenilen-1,5-diamina 2,4-disustituidos y aplicaciones de los mismos, y composiciones farmacéuticas y composiciones farmacéuticamente aceptables preparadas a partir de los mismos. | |
| PH12016501966A1 (en) | Compounds and compositions as toll-like receptor 7 agonists | |
| EA201791304A1 (ru) | Производные изохинолина для лечения вич | |
| MX381160B (es) | Agonistas del receptor de apelina y metodos de uso. | |
| EA201791256A1 (ru) | Производные хиназолина, применяемые для лечения вич | |
| MX378998B (es) | Agonistas de receptor de apelina (apj) de 4-hidroxi-3-(heteroaril) piridin-2-ona como para uso en el tratamiento de trastornos cardiovasculares. | |
| UY36175A (es) | 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas | |
| MX2017014375A (es) | Moduladores del ccr2. | |
| UY35972A (es) | Inhibidores macrocíclicos de fxia que tienen grupos heterocíclicos | |
| EA201692201A1 (ru) | Соединения и композиции в качестве агонистов toll-подобного рецептора 7 | |
| MX376062B (es) | Agonistas del receptor muscarinico. | |
| CL2017001650A1 (es) | Derivados de 5-[(piperazina-1-yl)-3-oxo-propilo]-imidazolidina-2,4-dionan como inhibidores adamts para el tratamiento oesteoartritis. | |
| PH12020551586A1 (en) | Oxysterols and methods of use thereof | |
| EA201692433A1 (ru) | Соединения ppar для применения при лечении фиброзных заболеваний | |
| MX2016013801A (es) | Moduladores del receptor acoplado a la proteina g 40 (gpr40) de pirrolidina para el tratamiento de enfermedades como la diabetes. | |
| PH12016501613A1 (en) | Pyrazines modulators of gpr6 | |
| MX2018005305A (es) | Nuevos antiestrogenos heterociclicos. | |
| MX2016011535A (es) | Ureas asimetricas p-sustituidas y usos medicos de las mismas. | |
| MX382092B (es) | Compuestos heterocíclicos para el tratamiento de enfermedades. |